Evidence map›Paper›PMID 23022545›Full record

ArticleActa biomaterialia2013

Controlled release of doxorubicin from pH-responsive microgels.

Mahrokh Dadsetan, K Efua Taylor, Chun Yong, Zeljko Bajzer, Lichun Lu, Michael J Yaszemski

Abstract read
In one paragraph

Article in Acta biomaterialia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Predicting drug delivery efficiency into tumor tissues through molecular simulation of transport in complex vascular networks.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mahrokh DadsetanDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
K Efua Taylor
Chun Yong
Zeljko Bajzer
Lichun Lu
Michael J Yaszemski

Funding

Injectable Osteoinductive Biodegradable CompositesR01EB003060 · NIBIB · MAYO CLINIC ROCHESTER · PI LU, LICHUN, YASZEMSKI, MICHAEL J · 2003 to 2014
$3.4M
OSTEOINDUCTIVE INJECTABLE DEGRADEABLE POLYMERIC SCAFFOLDR01AR045871 · NIAMS · MAYO CLINIC ROCHESTER · PI YASZEMSKI, MICHAEL J · 1999 to 2008
$2.7M
NIAMS NIH HHS R01 AR045871NIAMS NIH HHS R01 AR45871NIBIB NIH HHS R01 EB003060
6 · The paper itself

Abstract

Stimuli-responsive hydrogels have enormous potential in drug delivery applications. They can be used for site-specific drug delivery due to environmental variables in the body such as pH and temperature. In this study, we have developed pH-responsive microgels for the delivery of doxorubicin (DOX) in order to optimize its anti-tumor activity while minimizing its systemic toxicity. We used a copolymer of oligo(polyethylene glycol) fumarate (OPF) and sodium methacrylate (SMA) to fabricate the pH-responsive microgels. We demonstrated that the microgels were negatively charged, and the amounts of charge on the microgels were correlated with the SMA concentration in their formulation. The resulting microgels exhibited sensitivity to the pH and ionic strength of the surrounding environment. We demonstrated that DOX was efficiently loaded into the microgels and released in a controlled fashion via an ion-exchange mechanism. Our data revealed that the DOX release was influenced by the pH and ionic strength of the solution. Moreover, we designed a phenomenological mathematical model, based on a stretched exponential function, to quantitatively analyze the cumulative release of DOX. We found a linear correlation between the maximum release of DOX calculated from the model and the SMA concentration in the microgel formulation. The anti-tumor activity of the released DOX was assessed using a human chordoma cell line. Our data revealed that OPF-SMA microgels prolonged the cell killing effect of DOX.

Indexed as

MicrospheresAdsorptionCell DeathChemistry, PharmaceuticalDelayed-Action PreparationsDose-Response Relationship, DrugDoxorubicinFreeze DryingFumaratesGelsHumansHydrogen-Ion ConcentrationMethacrylatesMicroscopy, ConfocalMicroscopy, Electron, ScanningModels, ChemicalDelayed-Action PreparationsDoxorubicinFumaratesGelsMethacrylatesPolyethylene GlycolsSolutions

Identifiers

PMID23022545
PMCPMC3970914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.